EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Matching‐adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed‐duration venetoclax and ibrutinib in patients with treatment‐naïve chronic lymphocytic leukaemia

Talha Munir iD, Leyla Mohseninejad, Pal Rakonczai, Balazs Dobi, Sheng Xu, Keri Yang, Remus Vezan, Nicolás Martinez Calle

British Journal of Haematology · 2026-01 · 208 (1) · 321-324

DOI: 10.1111/bjh.70241 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 11.11.2025. Verfasst von Talha Munir und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Haematology, Leeds Teaching Hospitals NHS Trust, Level 3, Bexley Wing, St James's University Hospital, Leeds, UK. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BeOne Medicines Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

of HRs and contributed to the lack of significant differences in treatment effects. When comparing against CAPTIVATE, numerical benefit in favour of zanubrutinib was observed from 3 years onwards; further follow-up is needed to confirm the observed benefit. Furthermore, zanubrutinib showed a favourable safety profile versus V + I despite the longer treat-ment exposure in SEQUOIA versus V + I as a fixed-duration regimen. It should also be noted that AEs in CAPTIVATE were reported only if the incidence was >30% for any grade or >5% for grade 3+, further supporting the finding of a better safety profile for zanubrutinib. A prospective comparison between these two options is warranted to confirm our findings. This MAIC supports the use of both zanubrutinib and V + I as effective therapeutic options for TN CLL; longer fol- low-up is needed to observe any differences in PFS-INV. The observed safety differences between zanubrutinib and V + I suggest that zanubrutinib may have an impact on a patient's quality of life due to AEs, which may be considered at the time of treatment decision-making in TN CLL.

Schlagwörter

Stichwörter der Autor:innen

Bruton tyrosine kinase inhibitorchronic lymphocytic leukaemia (CLL)indirect comparisonzanubrutinib

Autor:innen und Institutionen

  • Department of Clinical Haematology, Leeds Teaching Hospitals NHS Trust, Level 3, Bexley Wing, St James's University Hospital, Leeds, UK.
  • Integrative Evidence Generation and Health Economics, BeOne Medicines Netherlands BV, Schiphol, The Netherlands.
  • Health Economics and Market Access, Evidera by PPD, Budapest, Hungary.
  • Global Statistics and Data Science, BeOne Medicines (Shanghai) Co, Ltd, Shanghai, China.
  • Integrative Evidence Generation and Health Economics, BeOne Medicines USA, Inc., Cambridge, Massachusetts, USA.
  • Clinical Development, Hematology, BeOne Medicines USA, Inc., Cambridge, Massachusetts, USA.

ORCID-Profile: Talha Munir

Förderung

  • BeOne Medicines Ltd.

Zitieren

APA

Munir, T., Mohseninejad, L., Rakonczai, P., Dobi, B., Xu, S., Yang, K., Vezan, R., & Calle, N. M. (2026). Matching‐adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed‐duration venetoclax and ibrutinib in patients with treatment‐naïve chronic lymphocytic leukaemia. British Journal of Haematology, 208(1), 321-324. https://doi.org/10.1111/bjh.70241

Vancouver

Munir T, Mohseninejad L, Rakonczai P, Dobi B, Xu S, Yang K, et al. Matching‐adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed‐duration venetoclax and ibrutinib in patients with treatment‐naïve chronic lymphocytic leukaemia. British Journal of Haematology. 2026;208(1):321-324. doi:10.1111/bjh.70241

BibTeX
@article{Munir2026,
  author = {Munir, Talha and Mohseninejad, Leyla and Rakonczai, Pal and Dobi, Balazs and Xu, Sheng and Yang, Keri and Vezan, Remus and Calle, Nicolás Martinez},
  title = {Matching‐adjusted indirect comparisons of efficacy and safety for zanubrutinib versus the combination of fixed‐duration venetoclax and ibrutinib in patients with treatment‐naïve chronic lymphocytic leukaemia},
  journal = {British Journal of Haematology},
  year = {2026},
  volume = {208},
  number = {1},
  pages = {321--324},
  doi = {10.1111/bjh.70241}
}
Kostenlos starten →